Key Details
Price
$1.12Annual ROE
-51.39%Beta
1.96Events Calendar
Next earnings date:
Feb 14, 2025Recent quarterly earnings:
Nov 06, 2024Recent annual earnings:
Feb 15, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
08 Nov '24 HC Wainwright & Co.
Buy28 Oct '24 HC Wainwright & Co.
Buy19 Sept '24 HC Wainwright & Co.
Buy16 Sept '24 JMP Securities
Market Outperform16 Sept '24 HC Wainwright & Co.
Neutral10 Sept '24 HC Wainwright & Co.
Neutral15 Aug '24 HC Wainwright & Co.
Neutral13 Mar '24 JMP Securities
Market Outperform20 Feb '24 HC Wainwright & Co.
Neutral19 Dec '23 Morgan Stanley
UnderweightMarket Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Prelude Therapeutics Incorporated doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD)
PRLD
zacks.com11 November 2024
Prelude Therapeutics (PRLD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
PRLD
globenewswire.com09 September 2024
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13, 2024, 4:00 PM CEST (10:00 AM EST)
Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
PRLD
globenewswire.com12 August 2024
Interim Phase 1 data for its first-in-class, highly selective IV SMARCA2 degrader, PRT3789, selected for an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 in September
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
PRLD
globenewswire.com03 June 2024
WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June.
All You Need to Know About Prelude Therapeutics Incorporated (PRLD) Rating Upgrade to Buy
PRLD
Zacks Investment Research04 October 2023
Prelude Therapeutics Incorporated (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
PRLD
GlobeNewsWire11 April 2023
Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline
FAQ
- What is the primary business of Prelude Therapeutics Incorporated?
- What is the ticker symbol for Prelude Therapeutics Incorporated?
- Does Prelude Therapeutics Incorporated pay dividends?
- What sector is Prelude Therapeutics Incorporated in?
- What industry is Prelude Therapeutics Incorporated in?
- What country is Prelude Therapeutics Incorporated based in?
- When did Prelude Therapeutics Incorporated go public?
- Is Prelude Therapeutics Incorporated in the S&P 500?
- Is Prelude Therapeutics Incorporated in the NASDAQ 100?
- Is Prelude Therapeutics Incorporated in the Dow Jones?
- When was Prelude Therapeutics Incorporated's last earnings report?
- When does Prelude Therapeutics Incorporated report earnings?
- Should I buy Prelude Therapeutics Incorporated stock now?
What is the primary business of Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated is a biotechnology company focused on developing innovative cancer therapies. They specialize in precision medicine, targeting specific genetic and molecular drivers of cancer to create effective treatments that improve patient outcomes and minimize side effects.
What is the ticker symbol for Prelude Therapeutics Incorporated?
The ticker symbol for Prelude Therapeutics Incorporated is NASDAQ:PRLD
Does Prelude Therapeutics Incorporated pay dividends?
No, Prelude Therapeutics Incorporated does not pay dividends
What sector is Prelude Therapeutics Incorporated in?
Prelude Therapeutics Incorporated is in the Healthcare sector
What industry is Prelude Therapeutics Incorporated in?
Prelude Therapeutics Incorporated is in the Biotechnology industry
What country is Prelude Therapeutics Incorporated based in?
Prelude Therapeutics Incorporated is headquartered in United States
When did Prelude Therapeutics Incorporated go public?
Prelude Therapeutics Incorporated's initial public offering (IPO) was on 25 September 2020
Is Prelude Therapeutics Incorporated in the S&P 500?
No, Prelude Therapeutics Incorporated is not included in the S&P 500 index
Is Prelude Therapeutics Incorporated in the NASDAQ 100?
No, Prelude Therapeutics Incorporated is not included in the NASDAQ 100 index
Is Prelude Therapeutics Incorporated in the Dow Jones?
No, Prelude Therapeutics Incorporated is not included in the Dow Jones index
When was Prelude Therapeutics Incorporated's last earnings report?
Prelude Therapeutics Incorporated's most recent earnings report was on 6 November 2024
When does Prelude Therapeutics Incorporated report earnings?
The next expected earnings date for Prelude Therapeutics Incorporated is 14 February 2025
Should I buy Prelude Therapeutics Incorporated stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions